JTV-519 Japan Tobacco.
Japan Tobacco is developing the mixed action ion channel blocker, JTV-519, which has potential use as an antiarrhythmic [285800]. The drug is a novel cardioprotectant derivative of 1,4-benzothiazepine for which phase I trials were completed in the third quarter of 1998; phase II trials started in the fourth quarter of 1998 for the potential treatment of myocardial infarction [320195]. Studies have shown that JTV-519 has a strong cardioprotective effect against catecholamine-induced myocardial injury and against ischemia/reperfusion injury [316749]. In experimental myofibrillar overcontraction models, it demonstrated greater cardioprotectant effects than propranolol, verapamil and diltiazem [171668].
Tse
H F
HF
Queen Mary Hospital, University Department of Medicine, Pokfulam, Hong Kong. hftse@hkucc.hku.hk
Lam
W F
WF
D000818:Animals; D017304:Annexin A5 / Q000378:metabolism / Q000502:physiology; D000889:Anti-Arrhythmia Agents / Q000378:metabolism / Q000494:pharmacology*; D002118:Calcium / Q000378:metabolism; D002316:Cardiotonic Agents / Q000378:metabolism / Q000494:pharmacology*; D016923:Cell Death / Q000187:drug effects; D007473:Ion Channels / Q000037:antagonists & inhibitors*; D008564:Membrane Potentials / Q000187:drug effects; D015428:Myocardial Reperfusion Injury / Q000188:drug therapy; D017682:Myocardial Stunning / Q000188:drug therapy; D009206:Myocardium / Q000473:pathology; D011493:Protein Kinase C / Q000378:metabolism / Q000502:physiology; D013841:Thiazepines / Q000378:metabolism / Q000494:pharmacology*
D017304:Annexin A5; D000889:Anti-Arrhythmia Agents; D002316:Cardiotonic Agents; D007473:Ion Channels; D013841:Thiazepines; C109183:K201 compound; D011493:Protein Kinase C; D002118:Calcium